Purification of beta cells from rat islets by monoclonal antibody-fluorescence flow cytometry
โ Scribed by Thomas R. Russell; Jack Noel; Nancye Files; Marylou Ingram; Alexander Rabinovitch
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 453 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Fluoresceinated monoclonal antibody plus flow cytometry was used to purify beta cells from mixed pancreatic islet endocrine cell populations. A2B5, a monoclonal antibody to a glycolipid on the surface of cells of neuroenโdocrine origin, was incubated with single cells dissociated from rat pancreatic islets. Antibodyโbound cells were labeled with fluoresceinated goat F(ab')~2~ antimouse immunoโglobulin and highly fluorescent cells were separated from less fluorescent cells on a Coulter EPICS IV cell sorter. Sorted cell populations were analyzed by radioimmunoassay for insulin, glucagon, and somatostatin. The highly fluorescent cell population was enriched sixfold for insulinโcontaining beta cells, indicating that islet beta cells are relatively enriched in A2B5 antigen and can be partially purified by this method.
๐ SIMILAR VOLUMES
## Abstract Monoclonal antibodies (mAbs) are used extensively for analytical, diagnostic and therapeutic applications. The purification of mAbs from cell culture supernatants typically consists of protein A, G or L affinity chromatography, often in association with other conventional chromatographi
Fluorescent antibodies are often used to measure the number of receptor sites on cells. The quanti- tative estimate of the number of receptor sites using this procedure assumes that the fluorescence intensity on a cell is proportional to the number of bound antibodies. Quenching may invalidate this
We have reported the isolation and specific in vitro properties of tumor-derived endothelial cells (TEC) from rat KMT-17 fibrosarcomas transplanted into rats. To develop antibodybased tumor vascular targeting therapy for solid tumors, we have generated monoclonal antibodies (MAbs) using passive immu